Listing sponsor / Agent
Dexia Securities France
Exchange / Market
Created in June 2008, CARMAT SAS is an innovative medtech start-up financed by TRUFFLE CAPITAL, EADS and the Professor Carpentier with additional funding from the French state innovation agency OSEO.
CARMAT has developed a totally implantable artificial heart which features the left and right ventricles. Its hi-tech design seeks to make the device as similar as possible to the human heart.
The CARMAT project has been spun off of the collaboration between Professor Carpentier in cardiovascular surgery and EADS on implementing biomaterials and cutting-edge technologies in the artificial heart field. The project is based on 15 years of development experience.
Initial Public offering